vTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Regulation FD Disclosure

Item 7.01Regulation FD Disclosure

Representatives of vTv Therapeutics Inc. (the Company) are
scheduled to display a poster entitled TTP399: A Liver-Selective
and Therapeutically Viable Glucokinase Activator: Results from a
6-Month Phase 2 Study at the Seventeenth Annual Levine-Riggs
Diabetes Research Symposium in Orlando, FL on March 29, 2017.The
poster presentation is attached hereto as Exhibit 99.1 and the
associated abstract is attached hereto as Exhibit 99.2.

The information in Item 7.01 of this Form 8-K (including Exhibit
99.1 and 99.2) shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference under the Securities Act
of 1933, as amended, except as expressly set forth by specific
reference in such a filing, regardless of any general
incorporation language in any such filing, unless the Company
expressly sets forth in such filing that such information is to
be considered filed or incorporated by reference therein.The
information set forth in the exhibits to this Form 8-K relating
to this item 7.01 shall not be deemed an admission as to the
materiality of any information in this report that is required to
be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01Financial Statements and Exhibits

(d) Exhibits

About vTv Therapeutics Inc. (NASDAQ:VTVT)

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

vTv Therapeutics Inc. (NASDAQ:VTVT) Recent Trading Information

vTv Therapeutics Inc. (NASDAQ:VTVT) closed its last trading session 00.00 at 6.18 with 17,051 shares trading hands.